Plasma cytokine levels predict response to corticosteroids in septic shock

Intensive Care Medicine

Volumn 42, Issue 12, 2016, Pages 1970-1979

  Bentzer, Peter ^a,b,c   Fjell, Chris ^a   Walley, Keith R ^a   Boyd, John ^a   Russell, James A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b LUND UNIVERSITY   (Sweden)

^c HELSINGBORG HOSPITAL   (Sweden)

Author keywords

Corticosteroids; Cytokines; Predictive biomarker; Propensity score matching; Septic shock

Indexed keywords

ALPHA2 INTERFERON; CD40 LIGAND; CORTICOSTEROID; CXCL1 CHEMOKINE; CYTOKINE; EOTAXIN; FIBROBLAST GROWTH FACTOR 2; FLT3 LIGAND; FRACTALKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROCORTISONE; HYPERTENSIVE FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; NORADRENALIN; VASOPRESSIN; BIOLOGICAL MARKER; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE;

ADULT; AGED; APACHE; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG POTENTIATION; FEMALE; FLUID RESUSCITATION; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PREDICTION; PROPENSITY SCORE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPTIC SHOCK; SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; ARTIFICIAL VENTILATION; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; ODDS RATIO; RANDOMIZED CONTROLLED TRIAL;

ADRENAL CORTEX HORMONES; AGED; BIOMARKERS; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; RESPIRATION, ARTIFICIAL; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 84963686144     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-016-4338-z     Document Type: Article

References (29)

1. Angus DC, van der Poll T (2013) Severe sepsis and septic shock. N Engl J Med 29(369):840–851
2. Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-Riffaud P, Bellissant E (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871
3. Annane D, Bellissant E, Bollaert PE, Briegel J, Confalonieri M, De Gaudio R, Keh D, Kupfer Y, Oppert M, Meduri GU (2009) Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 301:2362–2375
4. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317:653–658
5. Schumer W (1976) Steroids in the treatment of clinical septic shock. Ann Surg 184:333–341
6. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J, CORTICUS Study Group (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358:111–124
7. Annane D, Sébille V, Troché G, Raphaël JC, Gajdos P, Bellissant E (2000) A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 283:1038–1045
8. Boonen E, Vervenne H, Meersseman P, Andrew R, Mortier L, Declercq PE, Vanwijngaerden YM, Spriet I, Wouters PJ, Vander Perre S, Langouche L, Vanhorebeek I, Walker BR, Van den Berghe G (2013) Reduced cortisol metabolism during critical illness. N Engl J Med 368:1477–1488
9. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228
10. Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, Bozza MT, Castro-Faria-Neto HC, Bozza PT (2007) Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 11:R49
11. Fjell CD, Thair S, Hsu JL, Walley KR, Russell JA, Boyd J (2013) Cytokines and signaling molecules predict clinical outcomes in sepsis. PLoS One. doi:10.1371/journal.pone.0079207
12. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E (1993) Serum cytokine levels in human septic shock: relation to multiple system organ failure and mortality. Chest 103:565–575
13. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D, VASST Investigators (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358:877–887
14. Russell JA, Fjell C, Hsu JL, Lee T, Boyd J, Thair S, Singer J, Patterson AJ, Walley KR (2013) Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. Am J Respir Crit Care Med 188:356–364
15. Hansen BB (2004) Full matching in an observational study of coaching for the SAT. J Am Stat Assoc 99:609–618
16. Cepeda MS, Boston R, Farrar JT, Strom BL (2003) Optimal matching with a variable number of controls vs. a fixed number of controls for a cohort study trade-offs. J Clin Epidemiol 56:230–237
17. Austin PC (2011) Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10:150–161
18. Austin PC (2008) Assessing balance in measured baseline covariates when using many-to-one matching on the propensity-score. Pharmacoepidemiol Drug Saf 17:1218–1225
19. Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46:399–424
20. Russell JA, Walley KR, Gordon AC, Cooper DJ, Hébert PC, Singer J, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Dieter Ayers for the Vasopressin and Septic Shock Trial Investigators (2009) Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 37:811–818
21. Hunter CA, Jones SA (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol 16:448–457
22. Weber GF, Chousterman BG, He S, Fenn AM, Nairz M, Anzai A, Brenner T, Uhle F, Iwamoto Y, Robbins CS, Noiret L, Maier SL, Zönnchen T, Rahbari NN, Schölch S, Klotzsche-von Ameln A, Chavakis T, Weitz J, Hofer S, Weigand MA, Nahrendorf M, Weissleder R, Swirski FK (2015) Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis. Science 347:1260–1265
23. Bystry RS, Aluvihare V, Welch KA, Kallikourdis M, Betz AG (2001) B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol 2:1126–1132
24. Nowak JE, Wheeler DS, Harmon KK, Wong HR (2010) Admission chemokine (C-C motif) ligand 4 levels predict survival in pediatric septic shock. Pediatr Crit Care Med 11:213–216
25. Reinhart K, Menges T, Gardlund B, Harm Zwaveling J, Smithes M, Vincent JL, Tellado JM, Salgado-Remigio A, Zimlichman R, Withington S, Tschaikowsky K, Brase R, Damas P, Kupper H, Kempeni J, Eiselstein J, Kaul M (2001) Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: the RAMSES Study. Crit Care Med 29:765–769
26. Funk D, Doucette S, Pisipati A, Dodek P, Marshall JC, Kumar A, Cooperative Antimicrobial Therapy of Septic Shock Database Research Group (2014) Low-dose corticosteroid treatment in septic shock: a propensity-matching study. Crit Care Med 42:2333–2341
27. Póvoa P, Salluh JI, Martinez ML, Guillamat-Prats R, Gallup D, Al-Khalidi HR, Thompson BT, Ranieri VM, Artigas A (2015) Clinical impact of stress dose steroids in patients with septic shock: insights from the PROWESS-Shock trial. Crit Care 28(19):193
28. Keh D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O, Bercker S, Volk HD, Doecke WD, Falke KJ, Gerlach H (2003) Immunologic and hemodynamic effects of “low-dose” hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 167:512–520
29. Oppert M, Schindler R, Husung C, Offermann K, Gräf KJ, Boenisch O, Barckow D, Frei U, Eckardt KU (2005) Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med 33:2457–2464